Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Build A Bear Workshop Inc (BBW) vs Enveric Biosciences Inc (ENVB) Price & Performance

Build A Bear Workshop IncTrade
Enveric Biosciences IncTrade

Price performance (Past 24H)

Key statistics

Build A Bear Workshop Inc vs Enveric Biosciences Inc — how do they compare? Build A Bear Workshop Inc trades at $36.88 (market cap $467.15M), while Enveric Biosciences Inc trades at $1.45 (market cap $6.20M). The key difference: Build A Bear Workshop Inc is far larger — about 75.3× Enveric Biosciences Inc's market cap, and Build A Bear Workshop Inc pays a 2.47% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.

BBWENVB
Market Cap
$467.15M$6.20M
Sector
Consumer CyclicalHealth
52-Week High
$75.85$17.40
52-Week Low
$29.84$1.27
Enterprise Value
$566.59M$1.30M
Dividend Yield
2.47%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Build A Bear Workshop Inc

Build-A-Bear Workshop (BBW) trades at $36.86, up 6.19% today, with a bullish technical signal and strong analyst support. The stock exhibits attractive valuation metrics, including a P/E of 8.73 and P/S of 0.92, alongside robust profitability with a 10.48% net income margin and 35.87% ROE. Recent earnings have consistently beaten estimates, and the company maintains a debt-free balance sheet while executing a growth strategy focused on international expansion and brand partnerships.

The outlook for BBW is positive, driven by earnings momentum and a consensus price target of $62.50 implying significant upside. Key risks include near-term consumer spending volatility and execution of expansion plans, but strong fundamentals and shareholder returns via dividends support a favorable risk-reward profile for long-term investors.

Enveric Biosciences Inc

ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.

Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.

Returns comparison

Trailing returns across standard periods

About Build A Bear Workshop Inc

Build-A-Bear is a global retailer specializing in customizable stuffed animals. It offers an interactive make-your-own experience where customers choose, stuff, and dress their furry friends in-store or online.

Read more on BBW

About Enveric Biosciences Inc

Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.

Read more on ENVB